|
DE59609305D1
(de)
|
1995-11-17 |
2002-07-11 |
Biotechnolog Forschung Gmbh |
Epothilon-Derivate und deren Herstellung
|
|
EP1367057B1
(de)
|
1996-11-18 |
2008-09-17 |
Gesellschaft für biotechnologische Forschung mbH (GBF) |
Epothilone E und F
|
|
US6867305B2
(en)
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
JP4579351B2
(ja)
*
|
1996-12-03 |
2010-11-10 |
スローン−ケッタリング インスティトュート フォア キャンサー リサーチ |
エポチロンの合成とその中間体及びその類似物並びにその使用
|
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6380394B1
(en)
|
1996-12-13 |
2002-04-30 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6441186B1
(en)
*
|
1996-12-13 |
2002-08-27 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6660758B1
(en)
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
|
EP1201666A3
(de)
*
|
1997-02-25 |
2003-03-05 |
Gesellschaft für biotechnologische Forschung mbH (GBF) |
Seitenkettenmodifizierte Epothilone
|
|
US6605599B1
(en)
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
|
US6320045B1
(en)
|
1997-12-04 |
2001-11-20 |
Bristol-Myers Squibb Company |
Process for the reduction of oxiranyl epothilones to olefinic epothilones
|
|
US6365749B1
(en)
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
|
US6683100B2
(en)
|
1999-01-19 |
2004-01-27 |
Novartis Ag |
Organic compounds
|
|
US6498257B1
(en)
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
|
US6399638B1
(en)
|
1998-04-21 |
2002-06-04 |
Bristol-Myers Squibb Company |
12,13-modified epothilone derivatives
|
|
DE19826988A1
(de)
*
|
1998-06-18 |
1999-12-23 |
Biotechnolog Forschung Gmbh |
Epothilon-Nebenkomponenten
|
|
ES2175575T3
(es)
*
|
1998-08-05 |
2002-11-16 |
Biotechnolog Forschung Gmbh |
Agentes farmaceuticos que contienen n-oxido de epotilona a y/o n-oxidode epotilona b.
|
|
US6780620B1
(en)
|
1998-12-23 |
2004-08-24 |
Bristol-Myers Squibb Company |
Microbial transformation method for the preparation of an epothilone
|
|
US6596875B2
(en)
|
2000-02-07 |
2003-07-22 |
James David White |
Method for synthesizing epothilones and epothilone analogs
|
|
CN1205208C
(zh)
|
1999-02-22 |
2005-06-08 |
生物技术研究股份有限公司 |
C－21修饰的环氧噻酮类化合物
|
|
DE19907588A1
(de)
*
|
1999-02-22 |
2000-08-24 |
Biotechnolog Forschung Gmbh |
C-21 Modifizierte Epothilone
|
|
US20020058286A1
(en)
*
|
1999-02-24 |
2002-05-16 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6291684B1
(en)
|
1999-03-29 |
2001-09-18 |
Bristol-Myers Squibb Company |
Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
|
|
DK1169038T3
(da)
|
1999-04-15 |
2012-11-26 |
Bristol Myers Squibb Co |
Cykliske proteintyrosinkinaseinhibitorer
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
PE20010116A1
(es)
*
|
1999-04-30 |
2001-02-15 |
Schering Ag |
Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
|
|
US7125893B1
(en)
*
|
1999-04-30 |
2006-10-24 |
Schering Ag |
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
|
|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6518421B1
(en)
*
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
|
US6593115B2
(en)
|
2000-03-24 |
2003-07-15 |
Bristol-Myers Squibb Co. |
Preparation of epothilone intermediates
|
|
US6589968B2
(en)
*
|
2001-02-13 |
2003-07-08 |
Kosan Biosciences, Inc. |
Epothilone compounds and methods for making and using the same
|
|
UA75365C2
(en)
|
2000-08-16 |
2006-04-17 |
Bristol Myers Squibb Co |
Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
|
|
DE60225666T2
(de)
|
2001-01-25 |
2009-04-16 |
Bristol-Myers Squibb Co. |
Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
|
|
HUP0302567A2
(hu)
|
2001-01-25 |
2003-12-29 |
Bristol-Myers Squibb Co. |
Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra
|
|
WO2002058699A1
(en)
|
2001-01-25 |
2002-08-01 |
Bristol-Myers Squibb Company |
Pharmaceutical forms of epothilones for oral administration
|
|
US6893859B2
(en)
*
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
PL363363A1
(en)
|
2001-02-20 |
2004-11-15 |
Bristol-Myers Squibb Company |
Epothilone derivatives for the treatment of refractory tumors
|
|
CN1774253A
(zh)
|
2001-02-20 |
2006-05-17 |
布里斯托尔-迈尔斯斯奎布公司 |
用环氧丙酯酮衍生物治疗顽固性肿瘤
|
|
CZ20032291A3
(cs)
*
|
2001-02-27 |
2004-02-18 |
Gesellschaft Für Biotechnologische Forschung Mbh ( |
Degradace epothilonů
|
|
MXPA03008135A
(es)
|
2001-03-14 |
2003-12-12 |
Bristol Myers Squibb Co |
Combinacion de analogos de epotilona y agentes quimioterapeuticos para tratamiento de enfermedades proliferativas.
|
|
CA2449077A1
(en)
|
2001-06-01 |
2002-12-12 |
Gregory D. Vite |
Epothilone derivatives
|
|
TW200303202A
(en)
|
2002-02-15 |
2003-09-01 |
Bristol Myers Squibb Co |
Method of preparation of 21-amino epothilone derivatives
|
|
EP1483251B1
(en)
|
2002-03-12 |
2009-12-23 |
Bristol-Myers Squibb Company |
C3-cyano epothilone derivatives
|
|
AU2003218107A1
(en)
|
2002-03-12 |
2003-09-29 |
Bristol-Myers Squibb Company |
C12-cyano epothilone derivatives
|
|
TW200403994A
(en)
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
|
TW200400191A
(en)
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
US7008936B2
(en)
|
2002-06-14 |
2006-03-07 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
|
US6921769B2
(en)
|
2002-08-23 |
2005-07-26 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
EP1767535B1
(en)
|
2002-08-23 |
2009-12-02 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
EP2280014B1
(en)
|
2002-09-23 |
2013-10-23 |
Bristol-Myers Squibb Company |
Methods for the preparation, isolation and purification of epothilone B
|
|
EP1567487A4
(en)
|
2002-11-15 |
2005-11-16 |
Bristol Myers Squibb Co |
OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
|
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
BRPI0518286A2
(pt)
*
|
2004-11-18 |
2008-11-11 |
Bristol Myers Squibb Co |
microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço
|
|
US20060134214A1
(en)
*
|
2004-11-18 |
2006-06-22 |
Ismat Ullah |
Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
|
|
CA2607940C
(en)
|
2005-05-18 |
2009-12-15 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
SG10201407457UA
(en)
|
2006-05-16 |
2014-12-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
BRPI0718360A2
(pt)
|
2006-12-04 |
2013-11-12 |
Univ Illinois |
"composições e métodos para o tratamento do câncer com cupredoxinas e dna rico em cpg"
|
|
EP2534170B1
(en)
|
2010-02-12 |
2017-04-19 |
Pharmascience Inc. |
Iap bir domain binding compounds
|
|
US8846006B2
(en)
|
2011-01-20 |
2014-09-30 |
Board Of Regents, The University Of Texas System |
MRI markers, delivery and extraction systems, and methods of manufacture and use thereof
|
|
TWI603741B
(zh)
|
2011-06-10 |
2017-11-01 |
梅爾莎納醫療公司 |
蛋白質-聚合物-藥物共軛體
|
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
|
EP2924044B1
(en)
|
2012-11-17 |
2018-10-31 |
Beijing Shuobai Pharmaceutical Co., LTD |
Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
|
|
EP2928504B1
(en)
|
2012-12-10 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
EP2931316B1
(en)
|
2012-12-12 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
|
CA2914742A1
(en)
|
2013-06-11 |
2014-12-18 |
Bayer Pharma Aktiengesellschaft |
Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception
|
|
US9849191B2
(en)
|
2013-10-11 |
2017-12-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
PL3054992T3
(pl)
|
2013-10-11 |
2020-01-31 |
Asana Biosciences, Llc |
Koniugaty białko-polimer-lek
|
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
JP7320458B2
(ja)
|
2017-06-22 |
2023-08-03 |
メルサナ セラピューティクス インコーポレイテッド |
薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
|
|
EP3788032B1
(en)
|
2018-05-04 |
2024-01-24 |
Tagworks Pharmaceuticals B.V. |
Compounds comprising a linker for increasing transcyclooctene stability
|
|
WO2019212356A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B .V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
JP2022513400A
(ja)
|
2018-10-29 |
2022-02-07 |
メルサナ セラピューティクス インコーポレイテッド |
ペプチド含有リンカーを有するシステイン操作抗体－薬物コンジュゲート
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
JP2022537543A
(ja)
|
2019-06-17 |
2022-08-26 |
タグワークス ファーマシューティカルス ビー．ブイ． |
高速で且つ効率的なクリック放出の為の化合物
|
|
WO2023031445A2
(en)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
|
CA3238627A1
(en)
|
2021-11-25 |
2023-06-01 |
Christine Kohler |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
|
WO2023104941A1
(en)
|
2021-12-08 |
2023-06-15 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
|
EP4372000A3
(en)
|
2022-02-15 |
2024-07-17 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|